Wildtype

Market position

Wildtype is described in sources as the first startup permitted to sell cultivated seafood in the United States and is listed among cultured meat companies alongside Upside Foods, Believer Meats, Finless Foods, Mosa Meat, Aleph Farms and Eat Just. It operates in the cultivated meat and alternative protein segment, which one cited market report projects at roughly $3.25 billion by 2033. Commercial scale remains early, with availability limited to a small set of restaurants.

Sources identify Wildtype's principal differentiator as being the first company cleared by the FDA to sell cultivated seafood in the United States, giving it early market access ahead of other cultivated protein firms. Product-level differentiation rests on cell-grown real salmon that is neither farmed, wild-caught nor plant-based, marketed as sushi-grade and as avoiding contaminants associated with conventional seafood such as mercury, parasites and antibiotics. The company also emphasizes brewery-like bioreactor production and a consumer-facing brand developed to counter negative perceptions of lab-grown food.

Technology

Cellular agriculture: fish cells are cultivated in bioreactor systems that the company likens to a beer brewery, supplied with nutrients comparable to those fish consume in the wild. Production takes place in a converted former microbrewery in San Francisco's Dogpatch neighborhood, described as the company's first Fishery, and in a pilot plant opened in 2021 rated at 50,000 pounds of salmon per year with claimed scalability to 200,000 pounds. The company's cultivated salmon is grown from roe-derived cells, and the resulting product is positioned as sushi-grade with the nutritional profile of conventional salmon minus mercury, parasites and antibiotics. One source notes a bioreactor technology partnership with Solaris Biotech.

Go-to-market

Wildtype has pursued a chef- and restaurant-led launch strategy, seeding its cultivated salmon at notable independent and award-winning restaurants city by city, supported by press coverage and a consumer waitlist for early access to reservations and events. Branding and positioning work by PA Consulting targeted early adopters including chefs, food tastemakers and discerning consumers, and included naming, packaging concepts and social media guidelines intended to counter stereotypes about lab-created food. The company also engages publicly on regulatory issues, including litigation against state-level bans on cultivated food sales.

High-end and chef-driven restaurants, seafood distributors, and environmentally and health-conscious consumers seeking premium seafood without wild capture or farming; sushi applications are the primary culinary use case highlighted.

Geography

Headquartered in San Francisco, California, in the Dogpatch neighborhood, where the company also operates its first production "Fishery" and pilot plant. Commercial availability is US-only and concentrated in a handful of cities: Tucson (Kingfisher), San Francisco (Robin), Seattle (The Walrus and the Carpenter) and Washington, DC (barmini), with prior placements in Portland, Oregon (Kann) and Austin, Texas (Otoko, halted by state law).

History

Sources date the founding to 2016, when Elfenbein and Kolbeck co-founded the company (internal records list 2017). The founders explored government science grants in 2015 without success and turned to venture capital, raising a $3.5 million seed round in 2018 that funded initial R&D. In June 2019 Wildtype staged a tasting at a Portland, Oregon restaurant using its first cultivated salmon prototype, at a time when producing one pound took roughly 3.5 weeks and a single spicy salmon roll cost about $200 to make. A pilot production plant in San Francisco opened on June 24, 2021, when total funding stood at $16 million; by October 2021 the plant could produce 50,000 pounds of salmon annually with claimed scalability to 200,000 pounds. On May 28, 2025 the FDA cleared Wildtype's cultivated coho salmon for US sale, and the product appeared days later at Kann in Portland. In September 2025 Texas SB 261 banned cultivated food sales in the state, prompting partner restaurant Otoko to stop serving Wildtype and the company to sue alongside UPSIDE Foods and the Institute for Justice. Restaurant placements followed at Kingfisher in Tucson (November 2025) and barmini in Washington, DC (June 2026).

Risks & controversies

State-level regulation is a direct commercial risk: Texas SB 261, effective September 2025, banned the sale of cultivated foods in the state and forced partner restaurant Otoko to stop serving Wildtype salmon, prompting the company to sue. Production economics remain a challenge — early prototypes cost roughly $200 per spicy salmon roll and the company has stated it is working to reach cost parity with conventional wild and farmed salmon. Consumer perception of lab-grown food is another acknowledged obstacle, which the company addressed through a dedicated branding effort. Sources also conflict on basic facts: founding year is given as 2016 in public sources versus 2017 internally, total funding is reported variously as $117M and $123M, and one aggregator lists implausible employee counts and unrelated industry tags.